Puma Biotechnology Inc Stock Price, News & Analysis

Puma Biotechnology (NASDAQ: PBYI) has announced its participation in the upcoming TD Cowen 45th Annual Health Care Conference. The company's CEO Alan H. Auerbach will deliver a corporate presentation on March 5, 2025, at 11:10 a.m. ET at the Boston Marriott Copley Place.

The conference is scheduled to run from March 3-5, 2025. Investors and interested parties can access a live webcast of the presentation through Puma Biotechnology's website. The presentation recording will remain available for replay on the company's website for 30 days following the event.

Puma Biotechnology (NASDAQ: PBYI) has announced it will host a conference call to discuss its fourth quarter and full year 2024 financial results on Thursday, February 27, 2025, at 1:30 p.m. PT/4:30 p.m. ET. Investors can access the call via phone using 1-877-709-8150 (domestic) or 1-201-689-8354 (international) numbers.

A live webcast and presentation slides will be available on the Investors section of Puma's website. The call recording will be archived on the company's website for 90 days after the event.

Puma Biotechnology (NASDAQ: PBYI) has announced the approval of inducement restricted stock unit awards for two new non-executive employees. The Compensation Committee of Puma's Board of Directors approved the grant of 7,250 shares of common stock on February 4, 2025, under the company's 2017 Employment Inducement Incentive Award Plan.

The restricted stock units will vest over three years, with one-third vesting on February 1, 2026 (first anniversary), and one-sixth vesting every six months thereafter, contingent on continued employment. These awards were granted as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4).

Puma Biotechnology (NASDAQ: PBYI) announced the approval of inducement restricted stock unit awards for two new non-executive employees. The Compensation Committee approved grants covering 24,375 shares of Puma common stock under the company's 2017 Employment Inducement Incentive Award Plan.

The restricted stock units will vest over three years, with one-third vesting on January 1, 2026 (first anniversary), and one-sixth vesting every six months thereafter, contingent on continued employment. These awards were granted as employment inducements in compliance with Nasdaq Listing Rule 5635(c)(4).

Puma Biotechnology (NASDAQ: PBYI) announced that NERLYNX® (neratinib) has been included in the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Cervical Cancer. The drug is now listed as a second-line or subsequent therapy option for recurrent or metastatic cervical cancer patients with HER2-mutated tumors, receiving a Category 2A designation. The inclusion was based on results from the Phase II SUMMIT trial, which studied patients with histologically confirmed recurrent/metastatic cervical cancer and documented evidence of somatic, activating HER2 mutations.

Puma Biotechnology (NASDAQ: PBYI) announced the approval of an inducement restricted stock unit award for a new non-executive employee. The award, covering 7,500 shares of Puma common stock, was granted under the company's 2017 Employment Inducement Incentive Award Plan. The stock units will vest over three years, with one-third vesting on December 1, 2025, and one-sixth vesting every six months thereafter, contingent on continued employment. This grant complies with Nasdaq Listing Rule 5635(c)(4) as an employment inducement.

Puma Biotechnology (NASDAQ: PBYI) has initiated the ALISCA™-Breast1 Phase II trial of alisertib combined with endocrine therapy for hormone receptor-positive, HER2-negative metastatic breast cancer patients. The study will enroll up to 150 patients who have previously received CDK 4/6 inhibitors and at least two prior endocrine therapies. Patients will be randomized to receive alisertib at 30mg, 40mg, or 50mg doses. The trial's primary endpoints include objective response rate, duration of response, disease control rate, progression-free survival, and overall survival. Initial data is expected in 2025, with plans to discuss potential approval pathways with the FDA following trial outcomes.

Puma Biotechnology (NASDAQ: PBYI) reported strong Q3 2024 financial results with total revenue of $80.5 million, including $56.1 million in product revenue from NERLYNX® and $24.4 million in royalty revenue. The company posted a net income of $20.3 million ($0.41 per share), up from $5.8 million in Q3 2023. Operating cash flow was $11.0 million, with cash and equivalents of $97 million. The company updated its full-year 2024 guidance, projecting net product revenue of $187-190 million and net income of $15-17 million.

Puma Biotechnology (NASDAQ: PBYI) announced the approval of an inducement restricted stock unit award of 5,625 shares to a new non-executive employee. The award, granted under the company's 2017 Employment Inducement Incentive Award Plan, will vest over three years, with one-third vesting after the first year and one-sixth every six months thereafter, starting from November 1, 2024. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) as an employment inducement.